JPRN-UMIN000013258尚未招募1 期
Phase II clinical trial of WT1 peptide-based vaccine for pediatric patients with recurrent malignant glioma - Phase II clinical trial of WT1 peptide-based vaccine for pediatric patients with recurrent malignant glioma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 16years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)active infectious diseases 2)Severe Complications, including Heart failure, Renal faiure, Hapatic failure, ileus, uncontrolable DM, and so on 3)Other severe problems unsuitable for this study active infectious diseases 4)Active other cancers except for carcinoma in situ treated completely 5)Past history of Myeloproliferative diseases, MSD 6)Received allogeneic stem cell transplantation 7)Severe Psychological Problems
研究者
相似试验
已完成
不适用
Phase II clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with glioblastoma.GlioblastomaJPRN-UMIN000026965Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine35
已完成
1 期
Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors.Malignant solid tumors, Malignant lymphoma, Multiple Myeloma, Acute leukemiaJPRN-UMIN000002001Department of Cancer immunotherapy, Osaka University Graduate School of Medicine30
已完成
1 期
Phase 1 & 2 clinical trial using peptide vaccine for VEGFR1 & 2 in combination with S-1 and Cisplatin for patients with advanced gastric cancerunresectable or recurrent gastric cancerJPRN-UMIN000005007Osaka University, Graduate School of Medicine, Department of Gastroenterological Surgery30
已完成
1 期
Phase 1 & 2 clinical trial using peptide vaccine for VEGFR1 & 2 in combination with S-1 and Cisplatin for patients with advanced gastric cancer (HLA-A*0201)JPRN-UMIN000005345Osaka University, Graduate School of Medicine, Department of Gastroenterological Surgery15
已完成
不适用
Phase I/II clinical trial of WT1 peptide vaccine for the children with malignanciesJPRN-UMIN000002990Osaka Medical Center and Research Institute for Maternal and Child Health20